Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

Reports
Global Markets Direct’s wide variety of reports offer a targeted solution for marketing and strategic planning. These reports include in-depth company reports such as Company Market Share reports, which give a detailed breakdown of revenues by market and region, and Company Asset Reports, which give details of companies’ key assets by geography.
Company Strategic Analysis Reports include in-depth value chain and SWOT analysis, while Company Financial Deal Profiles highlight key financial deals that have shaped the company. Global Markets Direct also produces a wide range of market reports giving access to high value unique databases of information, examples include historic and forecast asset reports and market share reports covering value, volume, distribution and company shares.

Sectors and Geographies Covered
Global Markets Direct specializes in the Energy and Medical Equipment Markets. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers.

Research Methodology
With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.

Global Markets Direct
 

List of reports from Global Markets Direct

< prev 4  5  6  7  8  9  10  11  12  13  next >
Diabetes – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetes. 'Diabetes - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Diabetic Nephropathy – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Diabetic Nephropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy. 'Diabetic Nephropathy - Pipeline Review, H1 2012' ...  |  more...
$500.00
Retinal Vein Occlusion – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... the therapeutic development for Retinal Vein Occlusion, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion. 'Retinal Vein ...  |  more...
$500.00
Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... provides information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic ...  |  more...
$500.00
Malaria – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. 'Malaria - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... pipeline. This report provides information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the ...  |  more...
$500.00
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... Leukemia (CML, Chronic Myeloid Leukemia) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. ...  |  more...
$500.00
Human Papillomavirus Infections – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... the therapeutic development for Human Papillomavirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections. 'Human Papillomavirus ...  |  more...
$500.00
Hypercholesterolemia – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercholesterolemia. 'Hypercholesterolemia - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Cirrhosis – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cirrhosis. 'Cirrhosis - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Polio – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polio. 'Polio - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Retinoblastoma – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinoblastoma. 'Retinoblastoma - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Myelofibrosis – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelofibrosis . 'Myelofibrosis - Pipeline Review, H1 2012' is built using data ...  |  more...
$500.00
Skin Rash – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Skin rash, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin rash. 'Skin rash - Pipeline Review, H1 2012' ...  |  more...
$500.00
Renal Anemia – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Renal anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal anemia. 'Renal anemia - Pipeline Review, H1 2012' ...  |  more...
$500.00
Overactive Bladder – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Overactive Bladder. 'Overactive Bladder - Pipeline Review, H1 2012' ...  |  more...
$500.00
Opium (Opioid) Addiction – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... the therapeutic development for Opium (Opioid) Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction. 'Opium (Opioid) ...  |  more...
$500.00
Tetanus – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tetanus. 'Tetanus - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Arrhythmias – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arrhythmias. 'Arrhythmias - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Mucositis – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucositis. 'Mucositis - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Pertussis – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pertussis. 'Pertussis - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Diarrhea – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diarrhea. 'Diarrhea - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Respiratory Depression – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... for Respiratory Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Depression. 'Respiratory Depression - Pipeline Review, H1 2012' ...  |  more...
$500.00
Deep Vein Thrombosis (DVT) – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... provides information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Deep ...  |  more...
$500.00
Fatigue – Pipeline Review, H1 2012
3/19/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatigue. 'Fatigue - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
< prev 4  5  6  7  8  9  10  11  12  13  next >